Plavix Indications/Uses

Prevention of Atherothrombotic Events in Adults: Patients suffering from MI (from a few days until <35 days), ischaemic stroke (from 7 days until <6 months) or PAD.
Patients Suffering from Acute Coronary Syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI).
ST segment elevation acute MI, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Patients undergoing a stent placement following percutaneous coronary intervention (PCI), in combination with ASA.
Prevention of Atherothrombotic and Thromboembolic Events in Adults: Atrial Fibrillation (AF): In patients with AF at increased risk of vascular events who can take VKA therapy, VKA has been shown to be associated with a better clinical benefit than ASA alone or the combination of clopidogrel and ASA for the reduction of stroke.
In patients with AF who have at least 1 risk factor for vascular events and who cannot take VKA therapy (eg, specific risk of bleeding, physician assessment that patient is unable to comply with INR monitoring or that VKA use is inappropriate), clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. Clopidogrel in combination with ASA has been shown to reduce the rate of the combined endpoint of stroke, MI, non-CNS systemic embolism or vascular death, largely through a reduction in stroke (see Pharmacology: Pharmacodynamics under Actions).